Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer

This study has been completed.

Study NCT00113334 Information provided by M.D. Anderson Cancer Center

First Received: June 7, 2005 Last Updated: April 24, 2009 History of Changes

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Uncontrolled, Single Group Assignment
Condition:	Head and Neck Cancer
Intervention:	Drug: ABT-510

Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment Period: 06/10/05 through 03/02/07. All participants recruited at UT MD Anderson Cancer Center.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
ABT-510 (Thrombospondin)	No text entered.

Participant Flow: Overall Study

Baseline Characteristics

Reporting Groups

	Description
ABT-510 (Thrombospondin)	No text entered.

Baseline Measures

	ABT-510 (Thrombospondin)
Number of Participants [units: participants]	6
Age [units: years] Mean ( Full Range )	59 ( 43 to 64 )
Gender [units: participants]
Female	2
Male	4
Region of Enrollment [units: participants]
United States	6